IGKV2D-29 and neoplasm: Following scattered reports on the anti-cancer activity of some purinergic agonists,123,124 several clinical trials have been initiated to test the effectiveness of A2A antagonists, alone or in combination with other established chemotherapeutic or immune check-point blockers, in cancer therapy.125,126 In addition, the discovery that the tumour microenvironment is rich in extracellular ATP127 has fuelled trials designed to exploit this peculiar trait of tumours to confer selectivity to anticancer drugs.128